Fenwal Launched as Independent Corporation Following Completion of Divestiture From Baxter Healthcare Corporation.

ROUND LAKE, Ill., March 1 /PRNewswire/ -- Fenwal Inc. today announced its launch as an independent company. The new corporation is formed upon Baxter Healthcare Corporation completing the sale of its Transfusion Therapies business to Texas Pacific Group (TPG) and Maverick Capital, Ltd.

Established by TPG and Maverick Capital, Ltd. as an independently operated company, Fenwal now becomes one of the world's largest suppliers of products and services to the transfusion medicine industry. Since it was first established in 1949, the Fenwal brand has become recognized around the world as being synonymous with innovation in transfusion medicine.

"More than 50 years ago, this business was created with a single purpose: to support the mission of health-care providers to save and improve lives by providing high quality, innovative blood collection and processing products and services," explains Ron K. Labrum, President and CEO of Fenwal. "Today, this purpose is renewed as Fenwal once again becomes an independent company."

A pioneer in the science of transfusion medicine, Fenwal has introduced technological breakthroughs that have helped make blood collection and blood therapy a reality, and its advanced technologies have helped to ensure a safe and plentiful global blood supply. "We are focused on delivering new and better solutions and products that are developed in collaboration with our customers, and backed by the service and support expected of an industry leader," said Labrum. "As an independent business, Fenwal will have a singular focus and resources to continue investment in research and development, as well as pursue opportunities to shape the future of transfusion medicine."

Baxter will continue to provide certain manufacturing, distribution and support services to Fenwal for a period of time following the close, under transition agreements signed by the companies. "As the transfer of ownership occurs, our first priority is to maintain excellence in customer service and to execute a seamless transition of ownership," said Labrum.

TPG is a private investment partnership that was founded in 1992 and currently has more than $30 billion of assets under management. With offices in San Francisco, London, Hong Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park, Mumbai, Shanghai, Singapore and Tokyo, TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, joint ventures and restructurings. Please visit http://www.tpg.com/ .

Dallas and New York-based Maverick Capital, Ltd., a manager of private investment funds, is also an investor in this transaction.

Fenwal Inc. has five manufacturing plants located in Haina, Dominican Republic; San German and Maricao, Puerto Rico; La Chatre, France; and Bir Drassen, Tunisia. The company has approximately 3,500 employees worldwide, and annual sales of more than $500 million.

Fenwal's global team is focused on the development, manufacture and global marketing of products that allow blood centers, hospital blood banks, and plasma collection centers throughout the world to collect, separate, process, filter, store and administer whole blood and blood components for therapeutic use. To enhance the safety of transfusion medicine, Fenwal has focused on improved patient protection and has played a key role in developing automated systems and safety systems for whole blood collection. From the first fully automated blood cell separator to the most advanced apheresis technology, Fenwal continues to be a world leader in the development of innovations that change the practice of transfusion medicine.

Current product development is focused on systems that facilitate the process of cell separation using automated methods, systems to remove leukocytes (white cells) from blood components, and other processes to aid in ensuring a safe and available global blood supply. Please visit http://www.fenwalinc.com/ .

CONTACT: U.S. Media, Lisa Farrugia, +1-847-270-3965, or Tanya Tyska, +1-847-270-4918, or Europe Medi

in reference to:

"ROUND LAKE, Ill., March 1 /PRNewswire/ -- Fenwal Inc. today announced its launch as an independent company. The new corporation is formed upon Baxter Healthcare Corporation completing the sale of its Transfusion Therapies business to Texas Pacific Group (TPG) and Maverick Capital, Ltd. Established by TPG and Maverick Capital, Ltd. as an independently operated company, Fenwal now becomes one of the world's largest suppliers of products and services to the transfusion medicine industry. Since it was first established in 1949, the Fenwal brand has become recognized around the world as being synonymous with innovation in transfusion medicine. "More than 50 years ago, this business was created with a single purpose: to support the mission of health-care providers to save and improve lives by providing high quality, innovative blood collection and processing products and services," explains Ron K. Labrum, President and CEO of Fenwal. "Today, this purpose is renewed as Fenwal once again becomes an independent company." A pioneer in the science of transfusion medicine, Fenwal has introduced technological breakthroughs that have helped make blood collection and blood therapy a reality, and its advanced technologies have helped to ensure a safe and plentiful global blood supply. "We are focused on delivering new and better solutions and products that are developed in collaboration with our customers, and backed by the service and support expected of an industry leader," said Labrum. "As an independent business, Fenwal will have a singular focus and resources to continue investment in research and development, as well as pursue opportunities to shape the future of transfusion medicine." Baxter will continue to provide certain manufacturing, distribution and support services to Fenwal for a period of time following the close, under transition agreements signed by the companies. "As the transfer of ownership occurs, our first priority is to maintain excellence in customer service and to execute a seamless transition of ownership," said Labrum. TPG is a private investment partnership that was founded in 1992 and currently has more than $30 billion of assets under management. With offices in San Francisco, London, Hong Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park, Mumbai, Shanghai, Singapore and Tokyo, TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, joint ventures and restructurings. Please visit http://www.tpg.com/ . Dallas and New York-based Maverick Capital, Ltd., a manager of private investment funds, is also an investor in this transaction. Fenwal Inc. has five manufacturing plants located in Haina, Dominican Republic; San German and Maricao, Puerto Rico; La Chatre, France; and Bir Drassen, Tunisia. The company has approximately 3,500 employees worldwide, and annual sales of more than $500 million. Fenwal's global team is focused on the development, manufacture and global marketing of products that allow blood centers, hospital blood banks, and plasma collection centers throughout the world to collect, separate, process, filter, store and administer whole blood and blood components for therapeutic use. To enhance the safety of transfusion medicine, Fenwal has focused on improved patient protection and has played a key role in developing automated systems and safety systems for whole blood collection. From the first fully automated blood cell separator to the most advanced apheresis technology, Fenwal continues to be a world leader in the development of innovations that change the practice of transfusion medicine. Current product development is focused on systems that facilitate the process of cell separation using automated methods, systems to remove leukocytes (white cells) from blood components, and other processes to aid in ensuring a safe and available global blood supply. Please visit http://www.fenwalinc.com/ . CONTACT: U.S. Media, Lisa Farrugia, +1-847-270-3965, or Tanya Tyska, +1-847-270-4918, or Europe Media, Caroline Dekeuleneer, +32 (0)2 413 03 40 (phone), or +32 (0)486 58 18 39 (mobile), or Investors, Caroline Luz, +1-203- 656-2829, all of Fenwal Inc. Web site: http://www.fenwalinc.com/ http://www.tpg.com/"
- Press Release: Fenwal Launched as Independent Corporation Following Completion of Divestiture From Baxter Healthcare Corporation. - PR Newswire | HighBeam Research: Online Press Releases (view on Google Sidewiki)

7 Project Management Blogs You Can’t Miss

Clear PM – http://www.clearpm.com/

Cottage PM – http://www.cottagepm.com/

Kareem’s Blog – http://kareemshaker.com/

Papercut PM – http://papercutpm.tumblr.com/

http://www.torstenkoerting.com/

quantmleap – http://quantmleap.com/

FTR – http://ambidexter.ca/

in reference to: 7 Project Management Blogs You Can't Miss | pmStudent (view on Google Sidewiki)

Itchy for Earned Value (EVM)

EVM at it’s core is a way to measure performance in terms of cost, schedule, and technical performance. One of the key benefits I have heard cited regularly is that with EVM, you can tell early on whether or not a project is at risk.

in reference to:

"EVM at it’s core is a way to measure performance in terms of cost, schedule, and technical performance. One of the key benefits I have heard cited regularly is that with EVM, you can tell early on whether or not a project is at risk."
- Earned Value Introduction | pmStudent (view on Google Sidewiki)

"Just Tell Me What to Do!" - The Case for Active Project Management

“I just want to be told what to do and when,” says Kevin Kinsella, IT Regional Manger based in San Francisco. “The best project managers that I have worked with have been able to keep the project on track by telling me and the team when things were due or what may need my immediate attention.

in reference to:

"“I just want to be told what to do and when,” says Kevin Kinsella, IT Regional Manger based in San Francisco. “The best project managers that I have worked with have been able to keep the project on track by telling me and the team when things were due or what may need my immediate attention."
- "Just Tell Me What to Do!" - The Case for Active Project Management - www.projectmanagerplanet.com (view on Google Sidewiki)

Portfolio Management Done Right

Gather: Do a Project Inventory

in reference to:

"Portfolio Management Done Right"
- Portfolio Management Done Right - CIO.com - Business Technology Leadership (view on Google Sidewiki)

Improve execution track record thru solutions centered on the following

• Working with a management team to successfully determine the appropriate initiatives to consider, prioritize, and then select to address the opportunities at hand.
• Providing project management services when none existed to successfully implement initiative or projects on time, on budget, and with the highest quality.
• Developing a standard methodology, process and supporting tools to deliver products and services more efficiently to better meet the business demand.
• Creating custom and general training to key resources in order to enhance their ability to successfully manage and deliver current and future initiatives.

in reference to: Improve Your Execution in 2010 and Leapfrog Your Competition! | Project Management Solutions That Deliver Quantifiable Results (view on Google Sidewiki)

Engagement Approach

* Kickoff
* Assessment
* Recommendation
* Execution
* Transition



While every client is unique in the objectives they are trying to achieve, Fog City Consulting takes a very simple and consistent approach to each engagement. We begin with a “Welcome Meeting” to establish a solid relationship with the client. During this meeting, we review the scope of the engagement, meet the team, determine logistics, and plan the formal “Kickoff Meeting”. For each engagement, the team will follow our proven methodology based on 5 simple phases:

* Kickoff
* Assessment
* Recommendation
* Execution
* Transition

“Excellence is the expectation. Perfection is the goal.”

Deliver a solution that meets with your specification and provides your organization with the high client satisfaction.

in reference to:

"While every client is unique in the objectives they are trying to achieve, Fog City Consulting takes a very simple and consistent approach to each engagement. We begin with a “Welcome Meeting” to establish a solid relationship with the client. During this meeting, we review the scope of the engagement, meet the team, determine logistics, and plan the formal “Kickoff Meeting”. For each engagement, the team will follow our proven methodology based on 5 simple phases: Kickoff Assessment Recommendation Execution Transition Fog City Consulting is committed to providing our clients with the highest quality of work. Our mantra is “Excellence is the expectation. Perfection is the goal.” Throughout each engagement, we deliver a solution that meets with your specification and provides your organization with the high client satisfaction."
- Engagement Approach | Project Management Solutions That Deliver Quantifiable Results (view on Google Sidewiki)